A phase IV study on optimizing Pegasys plus Ribavirin for paitents with relapse chronic Hepatitis C.

Trial Profile

A phase IV study on optimizing Pegasys plus Ribavirin for paitents with relapse chronic Hepatitis C.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 May 2012 Planned end date changed from 31 Dec 2010 to 31 Dec 2012, as reported by Chinese Clinical Trial Register.
    • 09 Jan 2012 Actual end date (31 Dec 2010) added as reported by Chinese Clinical Trial Register.
    • 09 Jan 2012 Status changed from recruiting to completed as reported by Chinese Clinical Trial Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top